Patents by Inventor Bernard Krust

Bernard Krust has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 5550052
    Abstract: The invention relates to new purified antigens of the LAV virus. They have molecular weights of about 135,000 and 150,000 daltons. They are useful for the detection of LAV antibodies in human sera. They are produced by hybrid cell-lines resulting from the fusion of T4 lymphocytes and cells of the MOLT-4 cell line.
    Type: Grant
    Filed: September 11, 1992
    Date of Patent: August 27, 1996
    Assignees: Institut Pasteur, Centre National de la Recherche Scientifique
    Inventors: Luc Montagnier, Fran.cedilla.oise Rey, Bernard Krust, Fran.cedilla.ois Clavel
  • Patent number: 5470702
    Abstract: Character of the envelope transmembrane protein of human immunodeficiency virus type 2 (HIV-2) was carried out using murine polyclonal and monoclonal antibodies or patient sera specific for HIV-2 proteins. A 80-Mr glycoprotein (gp80) was produced in HIV-2 infected cells along with three other glycoproteins that were recently reported: the extracellular glycoprotein (gp125), the envelope glycoprotein precursor (gp140), and the transient dimeric form of gp140 (gp300). The gp125 and gp80 were detectable after the synthesis of gp140 and the formation of gp300. Among these four glycoproteins, only gp80 and gp125 were associated with HIV-2 virions. As the other glycoproteins, gp80 was recognized by all HIV-2 positive sera. A murine polyclonal antibody raised against the purified gp300 recognized all four glycoproteins.
    Type: Grant
    Filed: January 13, 1993
    Date of Patent: November 28, 1995
    Assignee: Institut Pasteur
    Inventors: Ara G. Hovanessian, Marie-Anne Rey, Anne G. Laurent, Bernard Krust, Luc Montagnier
  • Patent number: 5407811
    Abstract: This invention is directed to an isolated antibody specific for gp110 glycoprotein of a human immunodeficiency virus type 1 (HIV-1), and a hybridoma which produces such an antibody. HIV-1 is the causative agent of Acquired Immunodeficiency Syndrome (AIDS).
    Type: Grant
    Filed: September 24, 1992
    Date of Patent: April 18, 1995
    Assignee: Institut Pasteur and Centre National de la Recherche Scientific
    Inventors: Luc Montagnier, Bernard Krust, Solange Chamaret, Francois Clavel, Jean-Claude Chermann, Francoise Barre-Sinoussi
  • Patent number: 5312902
    Abstract: Four glycoproteins of apparent molecular weights 300,000, 140,000, 125,000, and 36,000 (gp300, gp140, gp125, and gp36) are detectable in human immunodeficiency virus type 2 (HIV-2) infected cells. The gp125 and gp36 are the external and transmembrane components, respectively, of the envelope glycoproteins of HIV-2 mature virions. The gp300, which is a dimeric form of gp140, the precursor of HIV-2 envelope glycoprotein, is probably formed by a pH dependent fusion in the endoplasmic reticulum. Such a doublet is also observed in cells infected with simian immunodeficiency virus (SIV), a virus closely related to HIV-2. On the other hand, the envelope glycoprotein precursor of HIV-1 does not form a dimer during its processing. Experiments carried out with various inhibitors of oligosaccharide trimming enzymes suggest that transient dimerization of the glycoprotein precursor is required for its efficient transport to the Golgi apparatus and for its processing.
    Type: Grant
    Filed: December 6, 1991
    Date of Patent: May 17, 1994
    Assignees: Institut Pasteur, C.N.R.S.
    Inventors: Luc Montagnier, Ara Hovanessian, Anne Laurent, Bernard Krust, Marie-Anne Rey
  • Patent number: 5208321
    Abstract: Characterization of the envelope transmembrane protein of human immunodeficiency virus type 2 (HIV-2) was carried out using murine polyclonal and monoclonal antibodies or patient sera specific for HIV-2 proteins. A 80-Mr glycoprotein (gp80) was produced in HIV-2 infected cells along with three other glycoproteins that were recently reported: the extracellular glycoprotein (gp125), the envelope glycoprotein precursor (gp140), and the transient dimeric form of gp140 (gp300). The gp125 and gp80 were detectable after the synthesis of gp140 and the formation of gp300. Among these four glycoproteins, only gp80 and gp125 were associated with HIV-2 virions. As the other glycoproteins, gp80 was recognized by all HIV-2 positive sera. A murine polyclonal antibody raised against the purified gp300 recognized all four glycoproteins.
    Type: Grant
    Filed: May 25, 1989
    Date of Patent: May 4, 1993
    Assignee: Institut Pasteur
    Inventors: Ara G. Hovanessian, Marie-Anne Rey, Anne G. Laurent, Bernard Krust, Luc Montagnier